Skip to main content

Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker

NEW YORK – Interpace Biosciences said on Monday that it has signed an exclusive license agreement with Rutgers, the State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody, Das-1, in the risk assessment of pancreatic cysts.

The license will give the Parsippany, New Jersey-based firm exclusive commercial rights to the patented technology.

Interpace's PancraGen assay applies molecular and clinical features from a patient's pancreatic cyst fluid to provide cancer risk assessment. The firm said the new biomarker will offer additional data regarding cancer risk to guide personalized patient management.

"We are thrilled to bring our discoveries from the bench to the bedside with the help of Interpace," Koushik Das, assistant professor of medicine at Washington University, said in a statement. "Utilizing Das-1 to identify patients at risk of pancreatic cancer has been our goal for many years."

Financial details of the agreement were not disclosed.

"The agreement with these highly respected institutions represents an important evolution of our GI franchise as we strive to provide the most comprehensive risk assessment tool available for physicians and their patients," Tom Burnell, president and CEO of Interpace, said in a statement.